Global Paediatric Gliomas Drugs Market, By Type (Low and High Grade), Diagnosis (Imaging Test, Brain or Spinal Cord, Tumour Biopsy and Others), Treatment (Surgery, Drug Treatments, Therapies), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Paediatric Gliomas Drugs Market Analysis and Size
The global paediatric gliomas drugs market is expected to witness significant growth during the forecast period. The cases of pediatric tumors are growaing worldwide, leading to the market's growth. Advanced diagnostic technology and new treatments are also major driving forces of the market. Several new cases of pediatric gliomas are rapidly growing, especially in the Asia Pacific region. Moreover, improving healthcare sector, government initiatives to improve public health and rising healthcare spending are boosting the growth for pediatric gliomas drugs market
Data Bridge Market Research analyses a growth rate in the global paediatric gliomas drugs market in the forecast period 2023-2030. The expected CAGR of global paediatric gliomas drugs market is tend to be around 6.50% in the mentioned forecast period. The market was valued at USD 1.02 billion in 2022, and it would grow upto USD 1.7 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Paediatric Gliomas Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Low and High Grade), Diagnosis (Imaging Test, Brain or Spinal Cord, Tumour Biopsy and Others), Treatment (Surgery, Drug Treatments, Therapies), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Aurobindo Pharma (India), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Thermo Fisher Scientific Inc. (U.S.), Baxter (U.S.), Hitachi, Ltd (Japan), Arbor Pharmaceuticals, Sun Pharmaceutical Industries, Ltd., Siemens Healthcare GmbH (Germany), Konninklije Philips N.V. (Netherlands)
|
|
Market Opportunities
|
|
Market Definition
Paediatric gliomas is a type of disorder that is characterized by the tumour of spinal cord or brain in children. It starts in glial cells that are present around the neurons, generating electrical impulses to transmit information, commonly known as glioma tumour. Moreover, the tumour causes complete damage in infratentorial brain functioning, including the brainstem and cerebellum. The most common symptoms in gliomas tumours include vomiting, headache, nausea, vision problems, and seizures.
Global Paediatric Gliomas Drugs Market Dynamics
Drivers
- Increase in Paediatric Population
The geriatric population is expected to increase the patient population globally, which boots the global paediatric gliomas drugs market in the forecast period. Currently, there are an estimated 2 billion children in the world ages zero to 14-years-old. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is projected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very viable route of administration.
Opportunities
- Increased Cases of Glioma
As per the records of the Case Reports in Oncology, 2018, around 200 cases were recorded globally for glioblastoma multiforme. Consequently, the market gains more attention and the growth is high because of the higher incidence of this diseased condition.
- Rising Healthcare Awareness
Health awareness amongst the population are rising, resulting in the prediction of drugs to boost market growth. The innovative launches in medications for the treatment of paediatric gliomas are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the treatment methods for this disease could limit the growth of the global paediatric gliomas drugs market over a forecast period.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. Several treatments and diagnostic procedures involve high cost that somewhat impedes market growth.
This global paediatric gliomas drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global paediatric gliomas drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Paediatric Gliomas Drugs Market Scope
The global paediatric gliomas drugs market is segmented on the basis of type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Low Grade
- High Grade
Diagnosis
- Imaging Test
- Brain or Spinal Cord
- Tumour Biopsy
- Others
Treatment
- Surgery
- Drug Treatments
- Therapies
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Paediatric Gliomas Drugs Market Regional Analysis/Insights
The global paediatric gliomas drugs market is analyzed and market size insights and trends are provided by type, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global paediatric gliomas drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.
Asia-Pacific dominates the market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Paediatric Gliomas Drugs Market Share Analysis
The global paediatric gliomas drugs market overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global paediatric gliomas drugs market.
Key players operating in the global paediatric gliomas drugs market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Amneal Pharmaceuticals LLC. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Baxter (U.S.)
- Hitachi, Ltd (Japan)
- Siemens Healthcare GmbH (Germany)
- Konninklije Philips N.V. (Netherlands)
Research Methodology: Global Paediatric Gliomas Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-